Stromacare SAS
Ana Hennino is currently the Chief Scientific Officer at Stromacare SAS since January 2022. With a background in Immunology, she completed her PhD at INSERM in Lyon in 2001. Ana has expertise in molecular mechanisms involved in apoptosis in the B cell compartment and has identified c-FLIP as a key regulator of B cell apoptosis in the germinal center. She also works as a CHARGEE DE RECHERCHE at INSERM, focusing on pancreatic ductal adenocarcinoma and the stroma/desmoplastic reaction in cancer. Ana's educational background includes a Master's degree in Immunology from École normale supérieure de Lyon and a PhD in Immunology from Université Claude Bernard Lyon 1.
This person is not in any teams
Stromacare SAS
StromaCare is opening a new therapeutic avenue by targeting the tumoral Stroma, which is known to play a key role in several solid cancers, with the objective to be essential in the numerous anticancer protocols of treatment. Stromacare won the Beatrice Denys Foundation 2021 Prize (Foundation for Medical Research). The company is located in Lyon, France.